This is Eamonn Hobbs profile on Linkedin. It is not update to reflect his latest appointment.
Eamonn Hobbs
President at Hobbs Medical Ventures, LLC
Greater New York City AreaMedical Devices
Current
Marvao Medical, Morris Innovative, Hobbs Medical Ventures, LLC
Previous
Delcath Systems, Inc, Cappella Cardiovascular Innovations, Inc., Sentinelle Medical
Education
University of Massachusetts at Lowell
Summary
CEO WITH PROVEN TRACK RECORD
Entrepreneurial and Intrapreneurial senior executive with over 30 years of demonstrated success in profitable medical device business creation, general management, sales and marketing, and product development.
High-integrity, passionate leader known for exceptional abilities in developing strong customer/physician relationships and building top-performing sales and operational teams. Areas of excellence include:
? Product Innovation & Development
? Successful Product Commercialization
? Financial Planning and Operational Performance
? Building Strong Sales Teams
? Influencing Government Policy
Optimizing Business Processes
Mergers and Acquisitions
Operational Integrations
Fund Raising
ANGIODYNAMICS, INC., (NASDAQ: ANGO), Queensbury, NY 1988 – FEBRUARY, 2009
Co-Founder, President, CEO, & Director
Co-founded a very successful medical device company that designs, develops, manufactures and markets minimally invasive devices for the targeted treatment of cancer and vascular disease. Company went from start up to leadership market share in core products against much larger, heavily entrenched competition.
Intrapreneurial endeavor of growing the business from a wholly-owned, green field start-up to an international stand-alone profitable public company, with over 600 employees at 4 facilities and fiscal year 2009 projected revenues of over $200 million.
? Company focuses on serving the needs of Interventional Radiologists, Interventional Neuroradiologists, Cardiologists, Surgeons, Nephrologists, Oncologists, and Dermatologists, with peripheral and neuro vascular, vascular access and cancer therapy medical devices.
? Worldwide sales and marketing, with direct sales forces both domestically and outside the USA (OUS), and additional stocking distributors OUS.
? Conducted extremely successful IPO (NASDAQ symbol ANGO) in May 2004, dramatically increasing shareholder value and liquidity.
Specialties:Medical Device Innovations and Commercialization
Industry Leadership
Customer/Physician Relationships
Unparalleled Recognition - SIR Fellowship
Business Development - Fund raising, IPO, Secondary
Mergers & Acquisitions - Numerous w/integrations
Experience
Chairman of the Board of Directors
Marvao Medical
January 2014 – Present (6 months)Galway, Ireland
Marvao has developed a potentially game changing platform technology that seeks to dramatically reduce catheter infections by revolutionizing how tunneled catheters are placed and maintained. In initial clinical data comprised of thousands of catheter days, the NexSite tunneling system has demonstrated a zero catheter related blood infection rate, (CRBI) and even more remarkable, NexSite has done this in some of the most challenging applications such as femoral dialysis catheters (which normally have a very high 5-7% CRBI rate). CRBI has risen to be one of the highest profile issues with hospital administrators since it is life threatening, treatment costs are very high but not reimbursed, and reducing the hospital CRBI rate recently became one of the top quality measures that determine each hospital’s across the board reimbursement rate for all of the hospital’s procedures under the new accountable care system. With this in mind, hospital administrators as well as clinicians have placed a very high priority on embracing any new technologies that materially reduce the CRBI rate. The NexSite system can be mated with any tunneled catheter system so it has broad market utility including applications in dialysis and central lines. NexSite Dialysis Catheters very recently received FDA clearance and CE Mark is pending.
Morris InnovativeChairman of the Board
Morris Innovative
December 2013 – Present (7 months)Bloomington, Indiana Area
Morris Innovative has developed and is commercializing two vascular closure device systems called FISH, which stands for Femoral Inserted Sheath Hemostasis. FISH CombiClose is a very unique combination working sheath/closure sheath system. The FISH InstaClose was very recently introduced procedure ending exchange system that delivers greatly simplified use, and shorter clinician learning curve. Both systems have multiple unique features and benefits that highly differentiate them from the competition. Morris has sold over 30,000 systems in the US so far, and recently received CE Mark approval, so the technology is very well proven.
President
Hobbs Medical Ventures, LLC
November 2013 – Present (8 months)Greater New York City Area
Founded by Eamonn Hobbs, Hobbs Medical Ventures is a consulting firm specializing in developing, delivering and implementing solutions for the medical device and combination medical device/pharmaceutical industries.
Mr. Hobbs is an entrepreneurial senior executive with over 30 years of demonstrated success in profitable medical device business creation, strategy, general management, sales and marketing, and product development.
He is a high-integrity, passionate leader known for exceptional abilities in developing strong customer/physician relationships and building top-performing sales and operational teams.
Areas of excellence include:?
• Strategy
• Product Innovation & Development?
• Successful Product Commercialization?
• Financial Planning and Operational Performance?
• Building Strong Sales Teams?
• Influencing Government Policy?
• Optimizing Business Processes
• Mergers and Acquisitions
• Operational Integrations
• Fund Raising
Board Member
Glens Falls Hospital
February 2013 – Present (1 year 5 months)Glens Falls, New York Area
Glens Falls Hospital provides comprehensive health care services to Warren, Washington, northern Saratoga, Essex, Hamilton, and northern Rensselaer counties. Our 27 regional facilities include health centers in Cambridge, Corinth, Granville, Greenwich, Hoosick Falls, Salem, Whitehall, and Wilton.
Member of the Strategic Planning Committee, Patient Safety and Quality Committee
Member of the Board of Directors
Harmonic Medical, Inc.
2012 – Present (2 years)Toronto, Canada Area
Member of the Audit, Governance and Compensation Committees.
Harmonic Medical is a Toronto based development stage company involved in the development of proprietary ultrasound guided high intensity focused ultrasound (HIFU) therapy systems.
Member, Board of Directors
Antares Pharma Inc.
2009 – Present (5 years)Ewing, New Jersey
Member Audit and Governance Committees
Antares Pharma, Inc. (NASDAQ: ATRS) is committed to developing and commercializing novel combination (drug and device) products utilizing the company’s unique, advanced drug delivery systems. ATRS products are patient focused: they typically improve safety and efficacy, reduce side effects and enable delivery at a lower dose. Antares advanced drug delivery systems are also well positioned for “life cycle extension” options.
Immediate Prior Chairman of the Board of Directors
Medical Device Manufacturers Association
2005 – Present (9 years)Washington D.C. Metro Area
The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, D.C. that represents independent manufacturers of medical devices, diagnostic products and health care information systems. MDMA seeks to improve the quality of patient care by influencing government policy, encouraging the development of new medical technology, and fostering the availability of beneficial innovative products.
Member, Executive, Governance, Membership and Compensation Committees
Delcath Systems, IncPresident & CEO
Delcath Systems, Inc
July 2009 – September 2013 (4 years 3 months)
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as ChemoSaturation (CS) for Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is approved and is pursuing reimbursement in the EU and is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver.
Chairman of the Board of Directors
Cappella Cardiovascular Innovations, Inc.
2009 – August 2013 (4 years)Galway, Ireland
Chairman of the Board (only independent member)
Early commercial stage (EU), venture capital backed company with a unique solution to treating coronary artery side branch disease.
Sentinelle MedicalMember of the Board of Directors
Sentinelle Medical
2008 – 2010 (2 years)Toronto, Canada Area
Member, Audit and Compensation Committees.
Sentinelle Medical Inc., established in 2004, is a private company based in Toronto, Canada that provides a suite of very high performance MR coils, and software solutions for GE, Toshiba and Siemens, providing health care providers with a fully integrated breast imaging and treatment planning system that result in the highest quality of patient care. Company achieved profitability and positive cash flow in Q4 2008. Very successful exit for investors upon sale of company to Hologic.
AngioDynamicsCo-founder, President & CEO
AngioDynamics
February 1988 – March 2009 (21 years 2 months)Glens Falls, New York Area
Co-founded a very successful medical device company that designs, develops, manufactures and markets image guided, minimally invasive devices for the targeted treatment of cancer and vascular disease. Company went from green field start up to leadership market share with premium positioning in core products against much larger, heavily entrenched competition.
Member of the Board of Directors
American College of Phlebology Foundation
2006 – 2009 (3 years)Washington D.C. Metro Area
Founding member of charitable scientific research and education foundation established in collaboration with its parent medical specialty society, American College of Phlebology, for the purpose of advancing the treatment of venous disease through research and education.
Assisted in the creation of the society’s first Strategic Plan.
Numerous committee memberships
Board Member
Society of Interventional Radiology Foundation
2002 – 2008 (6 years)Washington D.C. Metro Area
SIRF is a charitable scientific research and education foundation established in collaboration with its parent medical specialty society, Society of Interventional Radiology, for the purpose of advancing interventional radiology through research and education.
Sole Industry member of the Board; numerous committee positions held throughout tenure.
SVP/GM AngioDynamics Division
EZEM
1988 – 2004 (16 years)
VP Marketing
NAMICMedical Device Company focused on serving the needs of Interventional Cardiologists. Attained
1985 – 1988 (3 years)Glens Falls, New York Area
Medical Device Company focused on serving the needs of Interventional Cardiologists. Attained worldwide market leadership in Angiographic Manifolds and Control Syringes. Sold to Pfizer in 1992, later sold to Boston Scientific in 1997, and AngioDynamics in 2012.
Founder, CEO and President
Hobbs Medical, Inc.
1983 – 1985 (2 years)Stafford Springs, CT
Secured venture capital funding, founded and developed a profitable medical device firm focusing on trans-endoscopic interventional devices for Gastroenterologists. Sold company in 1985; remains in operation today as a private company: www.hobbsmedical.com.
Honors & Awards
Francis Cabot Lowell Alumni Award for Outstanding Achievement in Business
University of Massachusetts, Lowell
September 2010
Additional Honors & Awards
Honorary Fellow, Society of Interventional Radiology
